Category: DISEASE ADVANCES - Page 16 - Start Medical Product Development

Magnetic therapy headset shows improved cognitive function and mood in people with long COVID

October 1, 2026

A new study led by researchers from the Icahn School of Medicine at Mount Sinai and published in Brain Communications found that a transcranial low-amplitude magnetic field intervention delivered twice weekly into the brain through a noninvasive headset was associated with improvements in several measures of cognitive function and emotional well-being in people experiencing cognitive impairment associated with long COVID.

‘Mini-brains’ model myelin damage and regeneration, offering new tool for MS drug testing

October 1, 2026

Researchers have developed 3D “mini-brains” they hope will help speed up the search for much-needed drug treatments for multiple sclerosis (MS), an autoimmune condition affecting almost 3 million people worldwide. Their research has been published in the journal Nature Neuroscience.

Discovery explains how immune cells target DNA mutations to improve antibodies

October 1, 2026

Scientists at the Montreal Clinical Research Institute (IRCM), led by Université de Montréal medical professor Javier Di Noia, have shed light on a fundamental mystery in immunology: How do immune cells manage to concentrate a powerful mutagenic enzyme at precisely defined regions of DNA while largely sparing the rest of the genome from potentially dangerous damage?

BTL Expands EXOMIND® Platform with New FDA Clearances

October 1, 2026

MARLBOROUGH, Mass., Oct. 1, 2026 /PRNewswire/ — BTL Industries, a global leader in medical and wellness technologies, today announced expanded FDA clearances for EXOMIND®, its noninvasive brain stimulation platform.

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs

September 30, 2026

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

Viral infections can accelerate the progression of ALS, researchers find

September 30, 2026

A new study from McMaster University suggests that common viral infections—like influenza or COVID-19—may accelerate the onset and progression of amyotrophic lateral sclerosis, or ALS.

AI-guided light analysis could help assess skin cancer and reduce unnecessary biopsies

September 30, 2026

Skin cancer is the most common cancer in the United States and among the most common worldwide. Nearly 1.5 million new cases were diagnosed globally in 2024, including nearly 340,000 melanomas. Nonmelanoma skin cancers—primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—are even more common, with 5.4 million cases diagnosed annually in the U.S.

Blood RNA markers may flag lung cancer risk 10 years before diagnosis

September 30, 2026

Genetic markers in the blood that can signal lung cancer risk up to 10 years before a person is diagnosed have been discovered by University of Hawaiʻi researchers. The set of 31 tiny markers, called small noncoding RNAs, could eventually help identify people at higher risk while cancer remains clinically undetected.

Smartphone-enabled AI tool can detect widely underdiagnosed heart condition

September 30, 2026

A new Yale-developed artificial intelligence (AI) platform can detect individuals at risk for amyloid cardiomyopathy, an underdiagnosed cardiac condition, using data from a quick and accessible heart test.

Wearable stroke rehabilitation device gives patients the upper hand

September 30, 2026

A team led by University of Massachusetts Amherst researchers has developed a wearable wrist device powered by a machine-learning algorithm that can continuously track changes in arm movement impairment after a stroke. Monitoring those changes throughout rehabilitation could allow clinicians to adjust therapy in real time, tailoring care instead of relying on the current one-size-fits-all approach.